Dr. Reddy’s Laboratories Ltd. has announced an agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire its anti-vertigo drug brand Stugeron for $50.5 million (approximately ₹445 crore).
Under this deal, Dr. Reddy’s will acquire the Stugeron brand, including its key local variants Stugeron FORTE and Stugeron PLUS, along with associated assets across 18 markets spanning the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions. India and Vietnam will serve as key markets for the brand’s growth, the company said in a statement.
The acquisition marks Dr. Reddy’s entry into the anti-vertigo therapeutic space and is expected to bolster its Central Nervous System (CNS) portfolio in India and other emerging markets.
Stugeron contains Cinnarizine, an antihistamine used to treat vestibular disturbances and vertigo. It currently holds the top position in the Cinnarizine segment and ranks second in the overall anti-vertigo market in India.
“Dr. Reddy’s acquisition of the STUGERON brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio," said MV Ramana, chief executive officer of branded markets (India and Emerging Markets).
"Backed by our strong market access, we intend to extend the reach of STUGERON and its associated products across 18 key markets in the APAC and EMEA regions, including India and Vietnam," he added.